Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.46 which represents a slight increase of $0.05 or 0.05% from the prior close of $92.41. The stock opened at $92 ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...